Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELMD Stock Forecast 2026-2027
$26.06
Current Price
$217.35M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ELMD Price Targets
+45.8%
To High Target of $38.00
+42.0%
To Median Target of $37.00
+38.1%
To Low Target of $36.00
ELMD Price Momentum
+8.0%
1 Week Change
+10.9%
1 Month Change
+14.3%
1 Year Change
-10.5%
Year-to-Date Change
-15.2%
From 52W High of $30.73
+47.0%
From 52W Low of $17.73
📊 TOP ANALYST CALLS
Did ELMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Electromed is one of their latest high-conviction picks.
Latest ELMD Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ELMD has a bullish consensus with a median price target of $37.00 (ranging from $36.00 to $38.00). The overall analyst rating is N/A (N/A/10). Currently trading at $26.06, the median forecast implies a 42.0% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kyle Bauser at B. Riley Securities, projecting a 45.8% upside. Conversely, the most conservative target is provided by Kyle Bauser at Roth Capital, suggesting a 38.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELMD Analyst Ratings
3
Buy
0
Hold
0
Sell
ELMD Price Target Range
Low
$36.00
Average
$37.00
High
$38.00
Current: $26.06
Latest ELMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 12, 2026 | Freedom Broker | Buy | Maintains | $N/A | |
| Nov 19, 2025 | Freedom Broker | Buy | Maintains | $N/A | |
| Nov 13, 2025 | Roth Capital | Kyle Bauser | Buy | Reiterates | $36.00 |
| Aug 27, 2025 | Roth Capital | Kyle Bauser | Buy | Maintains | $35.00 |
| Aug 27, 2025 | Lake Street | Benjamin Haynor | Buy | Assumes | $36.00 |
| Jul 22, 2025 | Roth Capital | Kyle Bauser | Buy | Initiates | $29.00 |
| Feb 20, 2025 | B. Riley Securities | Kyle Bauser | Buy | Initiates | $38.00 |
| May 11, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $15.00 |
| Feb 16, 2023 | EF Hutton | Constantine Davides | Buy | Maintains | $15.00 |
| Feb 15, 2023 | Lake Street | Brooks O'Neil | Buy | Maintains | $26.00 |
| Dec 28, 2022 | Lake Street | Brooks O'Neil | Buy | Assumes | $20.00 |
| Sep 6, 2022 | EF Hutton | Constantine Davides | Buy | Initiates | $13.50 |
| Aug 5, 2022 | Lake Street | Kyle Bauser | Buy | Initiates | $20.00 |
| Nov 24, 2020 | Northland Capital Markets | Outperform | Initiates | $N/A | |
| Oct 18, 2019 | Dougherty & Co. | Buy | Initiates | $N/A |
Electromed Inc. (ELMD) Competitors
The following stocks are similar to Electromed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Electromed Inc. (ELMD) Financial Data
Electromed Inc. has a market capitalization of $217.35M with a P/E ratio of 25.3x. The company generates $68.86M in trailing twelve-month revenue with a 13.1% profit margin.
Revenue growth is +16.3% quarter-over-quarter, while maintaining an operating margin of +19.2% and return on equity of +20.2%.
Valuation Metrics
Market Cap
$217.35M
Enterprise Value
$201.96M
P/E Ratio
25.3x
PEG Ratio
0.6x
Price/Sales
3.2x
Growth & Margins
Revenue Growth (YoY)
+16.3%
Gross Margin
+78.4%
Operating Margin
+19.2%
Net Margin
+13.1%
EPS Growth
+40.3%
Financial Health
Cash/Price Ratio
+6.4%
Current Ratio
4.9x
Debt/Equity
0.2x
ROE
+20.2%
ROA
+13.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Electromed Inc. (ELMD) Business Model
About Electromed Inc.
What They Do
Manufacturer of innovative respiratory therapy devices.
Business Model
The company generates revenue by manufacturing and distributing advanced medical devices focused on respiratory therapy solutions. Its primary product, the SmartVest Airway Clearance System, targets patients with chronic respiratory conditions, ensuring a steady demand within the healthcare sector.
Additional Information
Electromed Inc. emphasizes research and development to stay competitive in the market. Its strategic partnerships with healthcare providers enhance the accessibility of its products, further solidifying its influence in the respiratory care segment.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
177
CEO
Mr. James L. Cunniff
Country
United States
IPO Year
2010
Website
smartvest.comElectromed Inc. (ELMD) Latest News & Analysis
Latest News
Quick Summary
Electromed (ELMD) shows above-average financial growth, indicating a strong potential to outperform the market.
Why It Matters
Electromed's strong financial growth signals potential for higher returns, attracting investor interest and possibly driving up stock prices.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Electromed (ELMD) reports strong revenue growth but faces intense competition for its SmartVest product from rivals like Tactile Medical and Baxter, raising concerns about its long-term market position.
Why It Matters
Electromed's strong revenue growth contrasts with competitive challenges and doubts about SmartVest's effectiveness, which may hinder its long-term market position and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
ISRG, EW, and ELMD are leveraging GenAI to improve diagnostics and workflows amid challenges like cost pressures, data risks, and macroeconomic headwinds in the MedTech sector.
Why It Matters
ISRG, EW, and ELMD's use of GenAI signals innovation in MedTech, potentially improving efficiency and competitiveness amid economic challenges, which may impact their stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Electromed, Inc. (ELMD) held its Q2 2026 earnings call, discussing financial performance and strategic updates. Detailed results and future outlook were shared.
Why It Matters
Electromed's Q2 2026 earnings call provides insights into financial performance, growth prospects, and market conditions, which can influence stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Electromed, Inc. reported record financial performance for the second quarter of fiscal 2026, indicating strong growth and positive business outcomes.
Why It Matters
Electromed's record financial performance signals strong growth and profitability, potentially increasing investor confidence and driving stock value upward.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Electromed, Inc. (ELMD) reported Q3 earnings of $0.32 per share, surpassing the Zacks Consensus Estimate of $0.27 and up from $0.22 per share a year earlier.
Why It Matters
Electromed's earnings beat expectations and show year-over-year growth, indicating strong financial performance and potential for increased investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ELMD Stock
What is Electromed Inc.'s (ELMD) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Electromed Inc. (ELMD) has a median price target of $37.00. The highest price target is $38.00 and the lowest is $36.00.
Is ELMD stock a good investment in 2026?
According to current analyst ratings, ELMD has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELMD stock?
Wall Street analysts predict ELMD stock could reach $37.00 in the next 12 months. This represents a 42.0% increase from the current price of $26.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Electromed Inc.'s business model?
The company generates revenue by manufacturing and distributing advanced medical devices focused on respiratory therapy solutions. Its primary product, the SmartVest Airway Clearance System, targets patients with chronic respiratory conditions, ensuring a steady demand within the healthcare sector.
What is the highest forecasted price for ELMD Electromed Inc.?
The highest price target for ELMD is $38.00 from Kyle Bauser at B. Riley Securities, which represents a 45.8% increase from the current price of $26.06.
What is the lowest forecasted price for ELMD Electromed Inc.?
The lowest price target for ELMD is $36.00 from Kyle Bauser at Roth Capital, which represents a 38.1% increase from the current price of $26.06.
What is the overall ELMD consensus from analysts for Electromed Inc.?
The overall analyst consensus for ELMD is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.00.
How accurate are ELMD stock price projections?
Stock price projections, including those for Electromed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 4:02 PM UTC